A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
ImMucin was shown to be able to induce a robust cellular immune response mediated via both CD4+ and CD8+ T lymphocytes and therefore, could potentially be more effective in the majority of the target population.
The purpose of this study is to evaluate the safety and initial efficacy of ImMucin, a novel peptide vaccine in metastatic tumors expressing the MUC-1 Tumor Associated Antigen (TAA).
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies|
- Determine the safety and tolerability of vaccination comprising the ImMucin vaccine
- combined with Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), in patients
- with multiple myeloma and other MUC-1 antigen-expressing metastatic carcinomas
- Determine objective anti-tumor response in patients treated with this regimen;
- Determine immune response in patients treated with this regimen
|Hadassah Medical Organization|
|Jerusalem, Israel, 91120|
|Principal Investigator:||Shimon Slavin, MD||Hadassah Medical Organization|